<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="evaluation" type="rst"/>
			<rel name="manner" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">3. Tailoring Immunotherapy in Real-Life Clinical Practice</segment>
<segment id="2" parent="1002" relname="span">After the histology-agnostic approval of pembrolizumab in mismatch repair</segment>
<segment id="3" parent="4" relname="preparation">( MMR)-deficient tumors ,</segment>
<segment id="4" parent="1003" relname="span">the predictive molecular pathology scenario in cancer immunotherapy changed radically .</segment>
<segment id="5" parent="1006" relname="span">For the first time in the history of medicine , a drug</segment>
<segment id="6" parent="5" relname="elaboration">( in this case , an immune-checkpoint inhibitor )</segment>
<segment id="7" parent="1007" relname="span">was approved</segment>
<segment id="8" parent="1008" relname="span">based on a specific molecular feature of the neoplasm ,</segment>
<segment id="9" parent="8" relname="elaboration">irrespective of its anatomical site of origin .</segment>
<segment id="10" parent="1010" relname="span">A multitude of different tools has been proposed</segment>
<segment id="11" parent="1011" relname="span">to inform immunotherapy ,</segment>
<segment id="12" parent="1013" relname="span">including morphology , immunohistochemistry</segment>
<segment id="13" parent="12" relname="restatement">( IHC ) , polymerase chain reaction</segment>
<segment id="14" parent="1015" relname="span">( PCR)-based techniques and next-generation technology assays , such as next-generation sequencing</segment>
<segment id="15" parent="14" relname="elaboration">( NGS )</segment>
<segment id="16" parent="1016" relname="span">or multiplex barcode technology</segment>
<segment id="17" parent="16" relname="elaboration">( e. g. , NanoString ) .</segment>
<segment id="18" parent="1018" relname="span">However , not all the available tools are validated for patients ’ selection in clinical practice ,</segment>
<segment id="19" parent="18" relname="manner">as shown in</segment>
<segment id="20" parent="21" relname="preparation">Figure 1</segment>
<segment id="21" parent="1020" relname="span">.</segment>
<segment id="22" parent="1023" relname="span">Among new biomarkers</segment>
<segment id="23" parent="22" relname="purpose">to select patients for immunotherapy ,</segment>
<segment id="24" parent="1025" relname="span">the tumor mutational burden</segment>
<segment id="25" parent="24" relname="elaboration">( TMB )</segment>
<segment id="26" parent="1024" relname="same_unit">has been shown a strong correlation with the response to some compounds .</segment>
<segment id="27" parent="1027" relname="span">TMB is defined by the total number of somatic nonsynonymous mutations per coding area of the tumor DNA .</segment>
<segment id="28" parent="1030" relname="attribution">It has been hypothesized</segment>
<segment id="29" parent="1030" relname="joint">that tumors with a higher TMB are more likely to express neoantigens</segment>
<segment id="30" parent="1030" relname="joint">and to induce a more robust immune response in the presence of immune checkpoint inhibitors .</segment>
<segment id="31" parent="1032" relname="span">Regrettably , the TMB analysis is considered expensive , time-consuming , and deceptive</segment>
<segment id="32" parent="31" relname="condition">if the analyses are carried out with an unsuitable NGS panel .</segment>
<segment id="33" parent="1035" relname="span">Another important facet in TMB analysis is represented by the lack of widely adopted guidelines and recommendations for its assessment and reporting .</segment>
<segment id="34" parent="1037" relname="span">Initially , TMB was determined</segment>
<segment id="35" parent="1038" relname="span">using wide approaches</segment>
<segment id="36" parent="35" relname="elaboration">( e. g. , whole exome sequencing ) ,</segment>
<segment id="37" parent="1036" relname="span">but more focused gene panels are currently being explored .</segment>
<segment id="38" parent="1041" relname="span">In addition , there are several indications</segment>
<segment id="39" parent="38" relname="elaboration">that TMB is not a universal biomarker ,</segment>
<segment id="40" parent="1040" relname="same_unit">as its value varies not only across tumor types but also across different genomic regions and during the time .</segment>
<segment id="41" parent="1039" relname="joint">This notion highlights the need for disease-specific TMB panels and thresholds .</segment>
<segment id="42" parent="1043" relname="span">Likewise , the analysis of the MMR status is troubled by the vastity of the existing diagnostic methods in the substantial absence of companion diagnostic</segment>
<segment id="43" parent="42" relname="elaboration">( CD ) tests .</segment>
<segment id="44" parent="1046" relname="span">In general , MMR IHC is mirrored by microsatellite instability</segment>
<segment id="45" parent="44" relname="elaboration">( MSI )</segment>
<segment id="46" parent="1045" relname="same_unit">in endometrial and colorectal cancers .</segment>
<segment id="47" parent="1049" relname="span">However , not all MMR-deficient tumors show MSI</segment>
<segment id="48" parent="47" relname="elaboration">( e. g. , breast cancers ) ,</segment>
<segment id="49" parent="1048" relname="same_unit">questioning the interchangeability of these analyses as pan-cancer predictive tests .</segment>
<segment id="50" parent="1051" relname="span">Hence , MMR/MSI assays have been originally developed by geneticists</segment>
<segment id="51" parent="1052" relname="joint">to identify Lynch syndrome families</segment>
<segment id="52" parent="1053" relname="span">and not for choosing the optimal drug</segment>
<segment id="53" parent="52" relname="purpose">to treat acquired tumors .</segment>
<segment id="54" parent="1054" relname="span">Given the wide heterogeneity in the repertoire of molecular alterations in immune-related genes across different tumor types</segment>
<segment id="55" parent="54" relname="elaboration">(</segment>
<segment id="56" parent="1021" relname="joint">Figure 2</segment>
<segment id="57" parent="1021" relname="joint">) , novel , efficient , reproducible , and reliable techniques coupled with tumor-specific methods and guidelines are needed .</segment>
<segment id="58" parent="1059" relname="span">Another important issue</segment>
<segment id="59" parent="58" relname="elaboration">related to the patient ’s selection for immunotherapy</segment>
<segment id="60" parent="1058" relname="same_unit">is represented by the PD-L1 analysis by IHC .</segment>
<segment id="61" parent="1061" relname="span">In this respect , important harmonization efforts have been made</segment>
<segment id="62" parent="1062" relname="span">to standardize both the preanalytical and interpretative phases of PD-L1 testing , at least in non-small cell lung cancer</segment>
<segment id="63" parent="62" relname="elaboration">( NSCLC ) .</segment>
<segment id="64" parent="1067" relname="span">The reproducibility of PD-L1 testing in real-life clinical practice</segment>
<segment id="65" parent="64" relname="elaboration">evaluated both for “ closed ” and “ open ” platforms ,</segment>
<segment id="66" parent="1066" relname="same_unit">showed overlapping results ,</segment>
<segment id="67" parent="1068" relname="span">particularly</segment>
<segment id="68" parent="67" relname="circumstance">when the 22C3 antibody clone was used .</segment>
<segment id="69" parent="1070" relname="span">On the other hand , there are several clues</segment>
<segment id="70" parent="71" relname="attribution">to advise</segment>
<segment id="71" parent="1071" relname="span">that the same interpretation guidelines should not be translated across different tumor types .</segment>
<segment id="72" parent="1076" relname="span">For example , the tumor proportion score</segment>
<segment id="73" parent="72" relname="elaboration">( TPS )</segment>
<segment id="74" parent="1075" relname="same_unit">works perfectly for lung cancer but not for head and neck cancer ,</segment>
<segment id="75" parent="1077" relname="span">where the combined positive score</segment>
<segment id="76" parent="75" relname="elaboration">( CPS )</segment>
<segment id="77" parent="1073" relname="same_unit">is more reliable .</segment>
<segment id="78" parent="1078" relname="span">These two scoring systems are rather different ,</segment>
<segment id="79" parent="1079" relname="span">given that the former considers only the percentage of PD-L1-positive neoplastic cells ,</segment>
<segment id="80" parent="1081" relname="span">while the latter combines all PD-L1-positive cells</segment>
<segment id="81" parent="80" relname="elaboration">( i. e. , tumor cells , lymphocytes , and macrophages )</segment>
<segment id="82" parent="1080" relname="same_unit">into the following formula .</segment>
<segment id="83" parent="84" relname="concession">Although the CPS can theoretically exceed the value of 100 ,</segment>
<segment id="84" parent="1083" relname="span">the maximum score is defined as 100 .</segment>
<segment id="85" parent="1085" relname="span">Fascinating perspectives are being provided by experimental models</segment>
<segment id="86" parent="85" relname="elaboration">addressing the plasticity of the cellular inflammatory response of the host .</segment>
<segment id="87" parent="1088" relname="span">There are several lines of evidence</segment>
<segment id="88" parent="87" relname="purpose">to suggest</segment>
<segment id="89" parent="1089" relname="span">that the myeloid-derived cell function is a finely tuned mechanism</segment>
<segment id="90" parent="89" relname="purpose">to control tumor growth .</segment>
<segment id="91" parent="1087" relname="evaluation">Specifically , both in local and hematopoietic niches , its crosstalk with the tumor cells as well as with exogenous stimuli , is based on the microbiota repertoire .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1004" relname="background"/>
<group id="1003" type="span" parent="2" relname="elaboration"/>
<group id="1004" type="multinuc" parent="1001" relname="span"/>
<group id="1005" type="multinuc" parent="1004" relname="joint"/>
<group id="1006" type="span" parent="1005" relname="same_unit"/>
<group id="1007" type="span" parent="1005" relname="same_unit"/>
<group id="1008" type="span" parent="7" relname="elaboration"/>
<group id="1010" type="span" parent="1004" relname="joint"/>
<group id="1011" type="span" parent="10" relname="purpose"/>
<group id="1012" type="span" parent="11" relname="elaboration"/>
<group id="1013" type="span" parent="1012" relname="span"/>
<group id="1014" type="multinuc" parent="1013" relname="elaboration"/>
<group id="1015" type="span" parent="1014" relname="contrast"/>
<group id="1016" type="span" parent="1014" relname="contrast"/>
<group id="1018" type="span" parent="1004" relname="joint"/>
<group id="1019" type="span" parent="1004" relname="joint"/>
<group id="1020" type="span" parent="1021" relname="preparation"/>
<group id="1021" type="multinuc" parent="1019" relname="span"/>
<group id="1022" type="multinuc" parent="1021" relname="joint"/>
<group id="1023" type="span" parent="1022" relname="same_unit"/>
<group id="1024" type="multinuc" parent="1022" relname="same_unit"/>
<group id="1025" type="span" parent="1024" relname="same_unit"/>
<group id="1027" type="span" parent="1021" relname="joint"/>
<group id="1028" type="span" parent="27" relname="elaboration"/>
<group id="1029" type="span" parent="1028" relname="span"/>
<group id="1030" type="multinuc" parent="1029" relname="span"/>
<group id="1031" type="span" parent="1029" relname="evidence"/>
<group id="1032" type="span" parent="1031" relname="span"/>
<group id="1033" type="span" parent="1032" relname="elaboration"/>
<group id="1034" type="multinuc" parent="1033" relname="span"/>
<group id="1035" type="span" parent="1034" relname="joint"/>
<group id="1036" type="span" parent="33" relname="elaboration"/>
<group id="1037" type="span" parent="37" relname="concession"/>
<group id="1038" type="span" parent="34" relname="means"/>
<group id="1039" type="multinuc" parent="1034" relname="joint"/>
<group id="1040" type="multinuc" parent="1039" relname="joint"/>
<group id="1041" type="span" parent="1040" relname="same_unit"/>
<group id="1042" type="span" parent="1034" relname="evidence"/>
<group id="1043" type="span" parent="1042" relname="span"/>
<group id="1044" type="span" parent="1043" relname="evidence"/>
<group id="1045" type="multinuc" parent="1044" relname="span"/>
<group id="1046" type="span" parent="1045" relname="same_unit"/>
<group id="1047" type="span" parent="1045" relname="concession"/>
<group id="1048" type="multinuc" parent="1047" relname="span"/>
<group id="1049" type="span" parent="1048" relname="same_unit"/>
<group id="1050" type="span" parent="1048" relname="evidence"/>
<group id="1051" type="span" parent="1050" relname="span"/>
<group id="1052" type="multinuc" parent="50" relname="purpose"/>
<group id="1053" type="span" parent="1052" relname="joint"/>
<group id="1054" type="span" parent="1051" relname="elaboration"/>
<group id="1058" type="multinuc" parent="1021" relname="joint"/>
<group id="1059" type="span" parent="1058" relname="same_unit"/>
<group id="1061" type="span" parent="1021" relname="joint"/>
<group id="1062" type="span" parent="61" relname="purpose"/>
<group id="1066" type="multinuc" parent="1021" relname="joint"/>
<group id="1067" type="span" parent="1066" relname="same_unit"/>
<group id="1068" type="span" parent="1021" relname="joint"/>
<group id="1069" type="span" parent="1021" relname="joint"/>
<group id="1070" type="span" parent="1069" relname="span"/>
<group id="1071" type="span" parent="69" relname="purpose"/>
<group id="1072" type="multinuc" parent="1070" relname="elaboration"/>
<group id="1073" type="multinuc" parent="1072" relname="joint"/>
<group id="1074" type="span" parent="1073" relname="same_unit"/>
<group id="1075" type="multinuc" parent="1074" relname="span"/>
<group id="1076" type="span" parent="1075" relname="same_unit"/>
<group id="1077" type="span" parent="1075" relname="elaboration"/>
<group id="1078" type="span" parent="1072" relname="joint"/>
<group id="1079" type="span" parent="78" relname="elaboration"/>
<group id="1080" type="multinuc" parent="79" relname="circumstance"/>
<group id="1081" type="span" parent="1080" relname="same_unit"/>
<group id="1082" type="span" parent="1021" relname="joint"/>
<group id="1083" type="span" parent="1082" relname="span"/>
<group id="1084" type="multinuc" parent="1083" relname="elaboration"/>
<group id="1085" type="span" parent="1084" relname="joint"/>
<group id="1086" type="span" parent="1084" relname="joint"/>
<group id="1087" type="span" parent="1086" relname="span"/>
<group id="1088" type="span" parent="1089" relname="attribution"/>
<group id="1089" type="span" parent="1087" relname="span"/>
	</body>
</rst>
